Urine Metals and Endothelial Function after a Single TACT Infusion in TACT-eligible Patients TACT-EndoMetal (Protocol # 14-35-H-07)
The Cardiology Department is recruiting patients for a research study to measure the levels of toxic metals in urine before and after the administration of a chelating solution.
If you qualify to take part in this study, there will be no additional cost to you.
Please call 305-674-2162 to learn if you might be eligible to take part in this study.
“The Trial to Assess Chelation Therapy-2 (TACT2)” (Protocol # 16-20-H-02)
Have you ever had a heart attack? Do you have diabetes? Are you age 50 or older?
If you answered ‘yes’ to these questions, you may be able to take part in a large national study of a new treatment, chelation and vitamins, for people with diabetes and heart disease. We are trying to determine if a new treatment, chelation, can prevent recurrent heart episodes, such as heart attacks, stroke, death, and others, by removing metal toxins from the blood.
If you qualify are agree to join the study, you will receive either active intravenous (IV) drug or IV placebo (inactive salt water solution). The IV is administered weekly for approximately 40 weeks. Each IV session lasts approximately three to four hours. In addition, you will take either high-dose oral vitamins and mineral supplements or identical inactive pills.
To learn more about this clinical trial of chelation for the treatment of coronary artery disease and diabetes, please contact our study coordinator at 305-674-2162.
“The COAPT Continued Access Study Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional MR (COAPT) Continued Access Study” (Protocol # 17-45-H-08)
We are enrolling patients in the COAPT CAS study that have moderate-to-severe or severe functional mitral regurgitation (MR). Functional MR occurs when the two leaflets of your mitral valve do not close properly causing blood to leak backward with each heartbeat.
If you have been determined to have symptoms due to heart failure despite being treated with currently available treatments, and are not an appropriate candidate for mitral valve surgery, you may be eligible to take part in this clinical trial.
To learn more about this clinical trial for the treatment of heart failure with functional MR, please contact our study coordinator at 305-674-2162.
“COBRA PzF Stenting to Reduce the Duration of Triple Therapy in Patients Treated with Oral Anticoagulation Undergoing Percutaneous Coronary Intervention” (Protocol #16-06-H-01)
Do you have coronary artery disease, a medical condition in which the arteries of your heart are partially blocked? Artery blockages can be fixed using a stent. The COBRA PzF™ Coronary Stent System (tube like device, currently approved by the FDA, manufactured by CeloNova BioSciences in San Antonio, Texas) is focused in the treatment of new lesions (damage) in coronary arteries with a shortened time of dual antiplatelet therapy (DAPT). Dual antiplatelet therapy means using aspirin and a second anti-clotting drug, usually Plavix, to help prevent blood clots from forming in arteries or stents.
To learn more about this clinical trial, please contact our study coordinator at 305-674-2121 ext. 50690.